Regulatory approval

Published by the Health Service Executive. Withdrawn

Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy.

This is written in the approval document.

Reimbursement

N/A

Citation

Fulvestrant Therapy, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6816/361_Fulvestrant_Therapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2016-11-11	Health Service Executive	Indication approved for reimbursement.